Kaliper Health的动态

In 2024, an estimated 234,580 new cases of lung cancer will be diagnosed in the US, and sadly, 125,070 people will lose the battle with this devastating disease. With lung cancer remaining one of the most challenging cancers to treat, the need for innovative treatment approaches is more urgent than ever. At Genomate Health, we are committed to transforming these statistics through AI-driven precision oncology. We are proud to share our latest research, published at American Society of Clinical Oncology (ASCO) 2024. Our work focuses on harnessing the power of AI and comprehensive molecular profiling to provide personalized treatment options for lung cancer patients, ultimately enhancing treatment efficacy. Read our full abstract here and discover how Genomate? is paving the way for more precise, effective lung cancer treatments: https://lnkd.in/gXhg-8mD #LungCancerAwareness #PrecisionOncology #AI #CancerTreatment ?? Anna Dirner, Robert Doczi, PhD, Dora Kormos, Dóra Lakatos, Márton Bolyácz, Dóra Tihanyi, Akos Takacs, ákos Boldizsár PhD, Mária Kocsis-Steinbach, Barbara Vodicska PhD, Réka Szalkai-Dénes, Edit Varkondi, Julia Deri, Dora Mathiasz, Istvan Valyi-Nagy, Richard SCHWAB M.D., Maud Kamal,PhD, Christophe Le Tourneau, Urban laszlo, Istvan Petak, MD, PhD

Lung cancer is the leading cause of death around the world, and unfortunately, patients with non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations face inevitable disease progression. ? ? Our priority at Johnson & Johnson Innovative Medicine is to challenge the current treatment landscape for these patients by developing unparalleled, personalized, targeted therapies for earlier intervention to create meaningful change.?? ? Luca Dezzani wrote an incredibly impactful article for @Endpoints News, detailing the immense need for additional therapies and our patient-centric approach to helping solve these problems.?? ? We believe lung cancer patients deserve better options for treatment. Learn more about how we plan to deliver at https://bit.ly/3xaoGiZ. #MyCompany #LungCancer #NSCLC #TargetedTherapy?

Researchers have discovered that proteins linked to cancer can show up in blood over 7 years before diagnosis. This game-changing finding could pave the way for earlier detection and treatment, possibly even through a simple at-home blood test in the future. More research is needed, but this is a huge step toward preventive cancer care. #CancerResearch #EarlyDetection #PreventiveCare https://hubs.li/Q02yzpT00

This week, the?American Association for Cancer Research?published their annual Cancer Disparities Progress Report for 2024 and one thing is made clear throughout: inequities in cancer care span the entire cancer journey—from screening to treatment and survivorship—underscoring the need for systemic change. Some key highlights from the report: 1?? Cancer Screening Inequities: Despite its life-saving potential, only 64% of eligible Asian and American Indian/Alaska Native individuals are up to date with cervical cancer screening, compared to 78% of White individuals, highlighting access barriers in preventive care. 2?? Treatment Inequities: Black and Hispanic women with triple-negative breast cancer (an aggressive type of breast cancer) are 18% and 13% less likely than White women to receive guideline-adherent treatments, leading to worse outcomes and higher mortality. 3?? Survivorship Care Inequities: Medically underserved populations face higher cancer mortality and worse quality of life after treatment, due to limited follow-up care, more side effects, and financial strain. Everyone should have access to quality care, regardless of who they are or where they live. This requires an approach that is culturally and linguistically accessible, reduces financial burdens, and breaks down logistical barriers for all. See the full study for more insights ↓ https://lnkd.in/gXgZ34k #healthequity #oncology #AACR

In this recent review article, we identified a massive heterogeneity in how end-of-life costs in cancer are being measured. In most cases (75%), the analysis is from the payer's perspective, and a big concern is that only 10% of the studies consider?indirect costs. This highlights how when we estimate the billionaire burden of cancer based on that evidence, we are probably excluding a critical portion of the real-world costs of the disease to society. Congratulations Prof. Rafael Vargas Alves and Soraya Camargo Ito Suffert MD, MBA, MSc for coordinating this study and all the co-authors involved. https://lnkd.in/dmNHupnC

I recently had the opportunity to write an article for?Endpoints News?to shed light on one of the most significant medical needs for people affected by lung cancer with EGFR exon 20 insertion mutations—the need for new and effective first-line treatment options.?? This mutation has historically responded poorly to many commonly used real-world first-line therapies for EGFR mutations. There is a tendency for rapid progression and inadequate outcomes among these patients, and thus a dire need for novel targeted approaches that can be used earlier in the course of?treatment.? At?Johnson & Johnson Innovative Medicine, the oncology team is?leading the way in?developing differentiated, immune-driven mechanisms of action and introducing new standards of care through a patient-centric research approach. Our hope is to transform the lives of people facing a lung cancer diagnosis.? Read the full article:?bit.ly/3wCoPeM #MyCompany #LungCancer #NSCLC #TargetedTherapy?

May is Skin Cancer Awareness Month! Did you know there are genes associated with an increased risk of developing skin cancer? Pathogenic variants in ????????2?? have been estimated to account for 35-40% of all familial melanomas. Other genes associated with increased melanoma risk include ??????1, ??????1, and ??????4. Additionally, basal cell nevus syndrome or Gorlin Syndrome, caused by pathogenic variants in ????????1, is associated with an increased risk of basal cell carcinoma. To learn more, read the National Cancer Institute's Genetics of Skin Cancer PDQ at ?? https://lnkd.in/gphVtjf #ICARE #InheritedCancerRegistry #InheritedCancer #SkinCancer #Melanoma #BasalCellCarcinoma #SquamousCellCarcinoma #BCC #SCC #CancerGenetics #CDKN2A #CDK4 #BAP1 #POT1 #PTCH1 #GorlinSyndrome #SkinCancerAwarenessMonth #MelanomaAwarenessMonth #CancerEducation #CancerAwareness National Cancer Institute (NCI) American Cancer Society Vanderbilt University Medical Center

Sending a big "thanks" to Martha for her comments highlighting the importance of panel testing for germline genetic mutations. Knowing Martha's story well after spending time with her family and shooting their video for our #FamilyGeneShare project, I know the outcome could have been much different for Martha and two of her children had the CDKN2A gene not been included in the panel option she was offered. Not long after Martha learned about her mutation, she noticed a mole on the side of her 20-year-old son's head and insisted he get it checked out. It was early melanoma, and genetic testing revealed he shared his mom's CDKN2A mutation. About a year prior to meeting the Kaiser family, our nonprofit organization funded testing for a family who had lost their son to melanoma in his early 20s. He was the same age as Martha's son when diagnosed. Sadly, his cancer was well advanced by the time it was discovered and by the time he learned he had a CDKN2A mutation. Unlike the Kaiser family, neither he nor his family knew they should be watching for both melanoma and pancreatic cancer. Knowledge is a powerful thing. Genetic testing, followed by appropriate surveillance, can be lifesaving! Be watching for My Faulty Gene's release over the next few weeks of the Kaiser family's video, along with many other compelling videos highlighting a number of different mutations. #Genetictestingsaveslives! #genetictesting #germline #hereditarycancer #previvor #survivor #knowyourrisk #familyhealthhistory #melanoma #pancreaticcancer #cdkn2a Myriad Genetics

Innovating Breast Cancer Treatment: A New Era of Hope TASK is proud to be conducting a clinical trial on a novel targeted therapy for breast cancer. This study is a significant step forward in our mission to advance health through innovative research. What’s the impact? The trial focuses on developing a treatment tailored to women with specific genetic markers associated with aggressive forms of breast cancer. This targeted approach aims to improve survival rates and quality of life, offering new hope to patients who previously had limited options. Why it matters: ??Personalised Medicine: This trial exemplifies the shift towards personalised medicine, where treatments are tailored to individual genetic profiles, leading to better outcomes. ??Improved Quality of Life: By focusing on targeted therapies, we aim to reduce side effects and enhance the quality of life for patients during and after treatment. ??Long-Term Benefits: Success in this trial could pave the way for more personalised treatment options, revolutionising breast cancer care for future generations. Stay informed about our progress and how we're working together to make a real impact in women's health. Learn more at task.org.za. #BreastCancerResearch #WomensHealth #TASKResearch #PersonalizedMedicine #HealthcareInnovation

September is Childhood Cancer Awareness Month. According to International Agency for Research on Cancer (IARC), Leukemias, lymphomas, and central nervous system tumors are the most common types of cancer in children. The distribution of these cancer types varies with age as children grow older, with the overall incidence showing two distinct peaks: one between ages 0–4 years and another between 15–19 years. As of 2024, several hundred clinical trials are active worldwide, many of which are part of large-scale international collaborations. These trials often focus on new therapeutic approaches, such as targeted therapies, immunotherapies, and strategies to reduce treatment-related side effects. Sources: https://lnkd.in/efsw9PX https://lnkd.in/e3uNpsnv. https://lnkd.in/ea_DgePW Image credit: International Agency for Research on Cancer (IARC): https://lnkd.in/e8nA3QfV ?? Are you looking for excellence in a CRO Contact us! ???? ____________________________________________________________________ Leading clinical trials with detail, efficiency, and excellence ??Share if others could benefit from this too! ?? To follow Hemex click the bell on the profile. #ChildhoodCancerAwareness #ChildhoodCancer #HealthEquity